USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
24
08
2020
accepted:
23
04
2021
revised:
08
04
2021
pubmed:
20
5
2021
medline:
14
1
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
The Ubiquitin-Specific Protease 22 (USP22) is a deubiquitinating subunit of the mammalian SAGA transcriptional co-activating complex. USP22 was identified as a member of the so-called "death-from-cancer" signature predicting therapy failure in cancer patients. However, the importance and functional role of USP22 in different types and subtypes of cancer remain largely unknown. In the present study, we leveraged human cell lines and genetic mouse models to investigate the role of USP22 in HER2-driven breast cancer (HER2
Identifiants
pubmed: 34007022
doi: 10.1038/s41388-021-01814-5
pii: 10.1038/s41388-021-01814-5
pmc: PMC8195738
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
USP22 protein, mouse
EC 3.4.19.12
Ubiquitin Thiolesterase
EC 3.4.19.12
Usp22 protein, human
EC 3.4.19.12
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4004-4018Références
Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.
pubmed: 20194857
doi: 10.1200/JCO.2009.24.9284
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.
pubmed: 31548545
doi: 10.1038/s41572-019-0111-2
Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev Cancer Treat Rev. 2014;40:259–70.
pubmed: 24080156
doi: 10.1016/j.ctrv.2013.09.002
Harbeck N. Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol. 2018;30:55–9.
pubmed: 29194077
doi: 10.1097/GCO.0000000000000431
Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, et al. HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2
pubmed: 28487443
pmcid: 5762201
doi: 10.1158/1078-0432.CCR-16-2191
Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115(Jun):1503–21.
pubmed: 15931389
pmcid: 1136989
doi: 10.1172/JCI23412
Koutelou E, Hirsch CL, Dent SYR. Multiple faces of the SAGA complex. Curr Opin Cell Biol. 2010;22:374–82.
pubmed: 20363118
pmcid: 2900470
doi: 10.1016/j.ceb.2010.03.005
Helmlinger D, Tora L. Sharing the SAGA. Trends Biochem Sci. 2017;42:850–61.
pubmed: 28964624
pmcid: 5660625
doi: 10.1016/j.tibs.2017.09.001
Lang G, Bonnet J, Umlauf D, Karmodiya K, Koffler J, Stierle M, et al. The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol. 2011;31:3734–44.
pubmed: 21746879
pmcid: 3165722
doi: 10.1128/MCB.05231-11
Kim D, Hong A, Park HI, Shin WH, Yoo L, Jeon SJ, et al. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 2017;232:3664–76.
pubmed: 28160502
doi: 10.1002/jcp.25841
Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, et al. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci USA. 2018;115:E9298–307.
pubmed: 30224477
pmcid: 6176615
doi: 10.1073/pnas.1807704115
Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell. 2012;46:484–94.
pubmed: 22542455
doi: 10.1016/j.molcel.2012.03.024
Zhang H, Han B, Lu H, Zhao Y, Chen X, Meng Q, et al. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. Cancer Lett. 2018;433:186–98.
pubmed: 29981430
doi: 10.1016/j.canlet.2018.07.002
Lin Z, Tan C, Qiu Q, Kong S, Yang H, Zhao F, et al. Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. Cell Disco. 2015;1:1–16.
doi: 10.1038/celldisc.2015.28
Xiao H, Tian Y, Yang Y, Hu F, Xie X, Mei J, et al. USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer. Biochem Biophys Res Commun. 2015;460:703–8.
pubmed: 25817787
doi: 10.1016/j.bbrc.2015.03.093
McCann JJ, Vasilevskaya IA, Neupane NP, Shafi AA, McNair C, Dylgjeri E, et al. USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair. Cancer Res. 2020;80:430–43.
pubmed: 31740444
doi: 10.1158/0008-5472.CAN-19-1033
Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, et al. Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol. 2016;18:954–66.
pubmed: 27501329
pmcid: 5026327
doi: 10.1038/ncb3396
Wang S, Zhong X, Wang C, Luo H, Lin L, Sun H, et al. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer. Cell Death Differ. 2020;27:3131–45.
pubmed: 32494025
pmcid: 7560726
doi: 10.1038/s41418-020-0568-2
Liu X, Yin Z, Xu L, Liu H, Jiang L, Liu S, et al. Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway. Cell Death Dis. 2021;12:173
pubmed: 33568633
pmcid: 7875967
doi: 10.1038/s41419-021-03435-y
Gao Y, Lin F, Xu P, Nie J, Chen Z, Su J, et al. USP22 is a positive regulator of NFATc2 on promoting IL2 expression. FEBS Lett. 2014;588:878–83.
pubmed: 24561192
doi: 10.1016/j.febslet.2014.02.016
Cai Z, Zhang MX, Tang Z, Zhang Q, Ye J, Xiong TC, et al. USP22 promotes IRF3 nuclear translocation and antiviral responses by deubiquitinating the importin protein KPNA2. J Exp Med. 2020;217:e20191174.
pubmed: 32130408
pmcid: 7201923
doi: 10.1084/jem.20191174
Huang X, Zhang Q, Lou Y, Wang J, Zhao X, Wang L, et al. USP22 deubiquitinates CD274 to suppress anticancer immunity. Cancer Immunol Res. 2019;7:1580–90.
pubmed: 31399419
doi: 10.1158/2326-6066.CIR-18-0910
Kosinsky RL, Wegwitz F, Hellbach N, Dobbelstein M, Mansouri A, Vogel T, et al. Usp22 deficiency impairs intestinal epithelial lineage specification in vivo. Oncotarget 2015;6:37906–18.
pubmed: 26431380
pmcid: 4741973
doi: 10.18632/oncotarget.5412
Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F, et al. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. 2020;27:1328–40.
pubmed: 31527800
doi: 10.1038/s41418-019-0420-8
Kosinsky RL, Helms M, Zerche M, Wohn L, Dyas A, Prokakis E, et al. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer. Cell Death Dis. 2019;10:911.
pubmed: 31801945
pmcid: 6892875
doi: 10.1038/s41419-019-2141-9
Martín-Pérez R, Palacios C, Yerbes R, Cano-González A, Iglesias-Serret D, Gil J, et al. Activated ERBB2/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-Dependent pathway. Cancer Res. 2014;74:1766–77.
pubmed: 24453000
pmcid: 4053205
doi: 10.1158/0008-5472.CAN-13-1747
Dittrich A, Gautrey H, Browell D, Tyson-Capper A. The HER2 Signaling Network in Breast Cancer–Like a Spider in its Web. J Mammary Gland Biol Neoplasia. 2014;19:253–70.
pubmed: 25544707
doi: 10.1007/s10911-014-9329-5
Baumann J, Wong J, Sun Y, Conklin DS. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer. 2016;16:551.
pubmed: 27464732
pmcid: 4964104
doi: 10.1186/s12885-016-2611-8
Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol. 2012;8:1–10.
doi: 10.1038/msb.2012.25
Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, et al. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. Nat Commun. 2019;10:2139.
pubmed: 31086176
pmcid: 6513990
doi: 10.1038/s41467-019-10138-8
Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B. et al. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. Blood . 2018;132:423–34.
pubmed: 29844011
pmcid: 6071563
doi: 10.1182/blood-2017-10-811760
Shubin AV, Demidyuk IV, Komissarov AA, Rafieva LM, Kostrov SV. Cytoplasmic vacuolization in cell death and survival. Oncotarget 2016;7:55863–89.
pubmed: 27331412
pmcid: 5342458
doi: 10.18632/oncotarget.10150
Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374–95.
pubmed: 27629041
pmcid: 5048378
doi: 10.15252/embr.201642195
Hayner JN, Shan J, Kilberg MS. Regulation of the ATF3 gene by a single promoter in response to amino acid availability and endoplasmic reticulum stress in human primary hepatocytes and hepatoma cells. Biochim Biophys Acta - Gene Regul Mech. 2018;1861:72–9.
pubmed: 29413899
doi: 10.1016/j.bbagrm.2018.01.002
Brooks AC, Guo Y, Singh M, McCracken J, Xuan YT, Srivastava S, et al. Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning. Curr Ther Res - Clin Exp. 2014;76:138–47.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9:ra17.
pubmed: 26884599
pmcid: 4815038
doi: 10.1126/scisignal.aac4380
Iurlaro R, Muñoz-Pinedo C. Cell death induced by endoplasmic reticulum stress. Vol. 283, FEBS Journal. Blackwell Publishing Ltd; 2016. p. 2640–52.
McConkey DJ. The integrated stress response and proteotoxicity in cancer therapy. Biochem Biophys Res Commun. 2017;482:450–3.
pubmed: 28212730
pmcid: 5319732
doi: 10.1016/j.bbrc.2016.11.047
Wang L, Dent SYR. Functions of SAGA in development and disease. Epigenomics Future Med Ltd. 2014;6:329–39.
doi: 10.2217/epi.14.22
Jeusset LMP, McManus KJ. Ubiquitin specific peptidase 22 regulates histone H2B mono-ubiquitination and exhibits both oncogenic and tumor suppressor roles in cancer. Cancers. 2017;9:167.
pmcid: 5742815
doi: 10.3390/cancers9120167
Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29:102–11.
pubmed: 18206973
pmcid: 2254522
doi: 10.1016/j.molcel.2007.12.015
Atanassov BS, Mohan RD, Lan X, Kuang X, Lu Y, Lin K, et al. ATXN7L3 and ENY2 coordinate activity of multiple H2B deubiquitinases important for cellular proliferation and tumor growth. Mol Cell. 2016;62:558–71.
pubmed: 27132940
pmcid: 4874879
doi: 10.1016/j.molcel.2016.03.030
Zhang T, Li N, Sun C, Jin Y, Sheng X. MYC and the unfolded protein response in cancer: synthetic lethal partners in crime? EMBO Mol Med. 2020;12:1–12.
doi: 10.15252/emmm.201911845
Zhang J, Luo N, Tian Y, Li J, Yang X, Yin H, et al. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt. Oncotarget 2017;8:24728–40.
pubmed: 28445968
pmcid: 5421883
doi: 10.18632/oncotarget.15798
Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol. 2017;11:682–95.
pubmed: 28417539
pmcid: 5467492
doi: 10.1002/1878-0261.12067
Lim CC, Xu JC, Chen TY, Xu JX, Chen WF, Hu JW, et al. Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner. Cancer Cell Int. 2020;20:45.
pubmed: 32063746
pmcid: 7011508
doi: 10.1186/s12935-020-1137-y
Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol. 2012;22:274–82.
pubmed: 22444729
doi: 10.1016/j.tcb.2012.02.006
Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 2011;137:1245–53.
pubmed: 21691749
doi: 10.1007/s00432-011-0998-9
Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: a cell’s response to stress. Life Sci. 2019;226:156–63.
pubmed: 30978349
pmcid: 7094232
doi: 10.1016/j.lfs.2019.04.022
Kopp MC, Larburu N, Durairaj V, Adams CJ, Ali MMU. UPR proteins IRE1 and PERK switch BiP from chaperone to ER stress sensor. Nat Struct Mol Biol. 2019;26:1053–62.
pubmed: 31695187
pmcid: 6858872
doi: 10.1038/s41594-019-0324-9
Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Cell Biochem. 2010;110:1299–305.
pubmed: 20506407
doi: 10.1002/jcb.22679
Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X. Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78/OCT4/lncRNA MIAT/AKT pathway. Am J Cancer Res. 2020;10:838–55.
pubmed: 32266094
pmcid: 7136914
Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, et al. Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Lett. 2017;404:79–88.
pubmed: 28716523
doi: 10.1016/j.canlet.2017.07.009
Ruggiero C, Doghman-Bouguerra M, Ronco C, Benhida R, Rocchi S, Lalli E. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. Mol Cell Endocrinol. 2018;474:57–64.
pubmed: 29474877
doi: 10.1016/j.mce.2018.02.010
Casas C. GRP78 at the centre of the stage in cancer and neuroprotection. Front Neurosci. 2017;11:1–15.
doi: 10.3389/fnins.2017.00177
Yang GH, Li S, Pestka JJ. Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (deoxynivalenol). Toxicol Appl Pharm. 2000;162:207–17.
doi: 10.1006/taap.1999.8842
Bailly C, Waring MJ. Pharmacological effectors of GRP78 chaperone in cancers. Biochemical Pharmacol Elsevier Inc. 2019;163:269–78.
doi: 10.1016/j.bcp.2019.02.038
Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, et al. Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell. 2016;29:805–19.
pubmed: 27238082
doi: 10.1016/j.ccell.2016.04.013
Millet A, Plaisant M, Ronco C, Cerezo M, Abbe P, Jaune E, et al. Discovery and optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a novel scaffold active against sensitive and resistant cancer cells. J Med Chem. 2016;59:8276–92.
pubmed: 27575313
doi: 10.1021/acs.jmedchem.6b00547
Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S, et al. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 2020;18:112.
pubmed: 32665011
pmcid: 7362500
doi: 10.1186/s12964-020-00612-y
Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:606–20. e7.
pubmed: 30118680
pmcid: 6786495
doi: 10.1016/j.molcel.2018.07.030
Chen X, Tukachinsky H, Huang CH, Jao C, Chu YR, Tang HY, et al. Processing and turnover of the Hedgehog protein in the endoplasmic reticulum. J Cell Biol. 2011;192:825–38.
pubmed: 21357747
pmcid: 3051819
doi: 10.1083/jcb.201008090
Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
pubmed: 20020197
doi: 10.1007/s10549-009-0674-9
Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, et al. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016;61:68–83.
pubmed: 26748827
doi: 10.1016/j.molcel.2015.12.008
Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T, et al. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 2011;71:5739–53.
pubmed: 21862633
doi: 10.1158/0008-5472.CAN-11-1896
Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017;45:6334–49.
pubmed: 28369619
pmcid: 5499659
doi: 10.1093/nar/gkx212
Dobin A, Gingeras TR. Mapping RNA-seq Reads with STAR. Curr Protoc Bioinforma. 2015;51:11.14.1–19.
doi: 10.1002/0471250953.bi1114s51
Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105–11.
pubmed: 19289445
pmcid: 2672628
doi: 10.1093/bioinformatics/btp120
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8